Circulating Tumor Cells


BreastCancer_700x233

New webinar: HER2, CTCs and tumor stemness

About 20–30% of breast cancer tumors overexpress the oncogene human epidermal growth factor receptor 2 (HER2), which – if not treated with a targeted anti-HER2 regimen – leads to higher aggressiveness and mortality. Recently, a number of studies have shown that expression of HER2 in circulating tumor cells (CTCs) varies compared to expression in primary tumors…. Read article →


10TopCTCsFAQs_700x233

Top 10 FAQs on circulating tumor cells

During the past 20 years, the interest in circulating tumor cells (CTCs) has increased dramatically due to their potential as circulating biomarkers in monitoring cancer progression and treatment. However, selecting and detecting CTCs from whole blood of cancer patients in the background of normal cells is very challenging. Since last summer, Dr. Siegfried Hauch, Director… Read article →


BreastCancer_Metastasis_700x233

Towards personalized cancer care: liquid biopsy for monitoring primary breast cancer

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses (1). At the time of diagnosis, a majority of patients (>90%) will have localized disease, which is typically treated with surgery, radiation and therapeutic agents. Localized disease is associated with improved five-year survival rates, relative to more advanced cancers… Read article →


CirculatingTumorCells_700x233

HER2-positive circulating tumor cells in primary breast cancer patients with HER2-negative tumors

In metastatic breast cancer patients, the presence of circulating tumor cells (CTCs) in the blood predicts shorter progression-free survival and lower overall survival (1). Persistent CTCs after treatment also predict a lack of therapeutic response (2). Although the prognostic significance of CTCs in metastatic patients is well established, fewer studies have examined CTCs in primary… Read article →